Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
Abstract Introduction Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) with different mechanisms o...
Main Authors: | Leslie R. Harrold, Heather J. Litman, Sean E. Connolly, Evo Alemao, Sheila Kelly, Sabrina Rebello, Winnie Hua, Joel M. Kremer |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-03-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40744-019-0149-3 |
Similar Items
-
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
by: Leslie R. Harrold, et al.
Published: (2023-02-01) -
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
by: Roy Fleischmann, et al.
Published: (2019-10-01) -
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01) -
The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs)
by: Zahra Samimi, et al.
Published: (2020-12-01) -
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
by: Yannick Degboé, et al.
Published: (2020-06-01)